The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles

BACKGROUND: Bevirimat, the prototype Human Immunodeficiency Virus type 1 (HIV-1) maturation inhibitor, is highly potent in cell culture and efficacious in HIV-1 infected patients. In contrast to inhibitors that target the active site of the viral protease, bevirimat specifically inhibits a single cl...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Nguyen, Albert T, Feasley, Christa L, Jackson, Ken W, Nitz, Theodore J, Salzwedel, Karl, Air, Gillian M, Sakalian, Michael
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2011
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3267693/
https://ncbi.nlm.nih.gov/pubmed/22151792
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-4690-8-101
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars